All In Biotech

Drug Trial Radar · NCT06411912

A Study of NIDO-361 in Patients With SBMA

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NIDO-361 in Patients With Spinal and Bulbar Muscular Atrophy (SBMA)

Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

54

Actual

Start

Mar 1, 2024

Primary completion

Oct 22, 2025

Study completion Oct 22, 2025

Sponsor

Lead sponsor
Nido Biosciences, Inc.Industry
Sponsor type
Industry
First posted
May 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and efficacy of NIDO-361 in adult patients with Spinal and Bulbar Muscular Atrophy (SBMA).

Conditions

  • Spinal and Bulbar Muscular Atrophy
  • Kennedy's Disease

Interventions

  • NIDO-361Drug

    Tablets containing 100mg of NIDO-361 for oral administration.

  • PlaceboDrug

    Placebo oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Analysis of Thigh and Total Lean Muscle Volume (LMV) [A+B+C]Time frame: Baseline, Day 180, Days 360-374 (Last Visit)
  2. Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)Time frame: Through study completion, an average of 1 year
  3. Number of Participants Discontinuing Study Drug and Number of Participants' DeathsTime frame: Through study completion, an average of 1 year
  4. Total Number of Mild, Moderate, and Severe Adverse Events (AEs) Across All ParticipantsTime frame: Through study completion, an average of 1 year

Locations

5 sites in 4 countries. Site status is shown where the registry gives one.

  • Rigshospitalet, Klinik for Nerve- og Muskelsygdomme & Copenhagen Neuromuscular Center

    Copenhagen, Denmark

  • IRCCS Istituto Neurologico Carlo Besta

    Milan, Italy

  • Azienda Ospedale Università di Padova

    Padova, Italy

  • Kyungpook National University Chilgok Hospital

    Daegu, South Korea

  • University of College London Hospital (UCLH)

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.